A review of two new books that attack the DSM-5, psychiatry’s “bible”

by | Jun 10, 2013 | antidepressants, antipsychotic drugs, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, scientific misconduct

I reviewed two books now circulating about the DSM and the current controversy over the DSM-5 for The American Scholar — see review here. The two books are The Book of Woe: The DSM and the Unmaking of Psychiatry by Gary Greenberg, and Saving Normal: An Insider’s...

Martin Keller, principal investigator of Paxil study 329, retires from Brown University

by | Sep 5, 2012 | antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct

I just learned that Dr. Martin Keller, principal investigator of the controversial Paxil study 329, has retired from his position as a professor of psychiatry at Brown University — see here. As Pharmalot notes, Keller quietly retired June 30 in the midst of an...

Calls for action against authors of controversial Paxil study are getting louder

by | Sep 4, 2012 | antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration

In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the...

Why academic researchers involved in fraudulent Paxil study escape scrutiny

by | Aug 7, 2012 | antidepressants, clinical trials, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration

The Chronicle of Higher Education this week ponders why various universities have taken no action against the academic researchers who co-authored the notorious Paxil study that formed the crux of GlaxoSmithKline’s recent $3 billion settlement with the...

New York AG’s office should take a bow for GlaxoSmithKline’s record-breaking fine

by | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing

I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...

Is the FDA violating its own mandate to approve safe drugs?

by | Apr 27, 2012 | antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized

Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at Brandeis University. The...